Newsroom - Best in Class Assays, Reagents and Clinical Lab Services - Invivoscribe

Newsroom – Best in Class Assays, Reagents and Clinical Lab Services2026-05-15T17:11:41-07:00

Newsroom

Newsroom

LATEST PUBLICATIONS

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

2021-02-11T20:11:02-08:00October 8th, 2020|

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

2021-02-11T20:13:51-08:00August 27th, 2020|

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

2021-02-11T20:26:38-08:00July 22nd, 2020|

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

2021-02-11T21:43:52-08:00June 8th, 2020|

Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing

2021-02-11T21:47:46-08:00May 19th, 2020|

LATEST PRESS

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

2021-02-26T19:13:49-08:00March 28th, 2017|

Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software

2021-02-26T19:13:58-08:00February 28th, 2017|

Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits

2021-02-26T19:14:04-08:00February 14th, 2017|

Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits

2021-02-26T19:14:11-08:00January 31st, 2017|

Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

2021-02-26T19:14:23-08:00November 14th, 2016|

CONFERENCES

No conferences from the last year found.